3,394 results on '"Patel, Keyur"'
Search Results
252. P084: Microsatellite instability and high tumor mutational burden is concordant with loss of mismatch repair proteins
253. Bringing high availability to BGP: A survey
254. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
255. Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion
256. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma
257. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia
258. Secondary mutations as mediators of resistance to targeted therapy in leukemia
259. Accuracy of Fibroscan, Compared With Histology, in Analysis of Liver Fibrosis in Patients With Hepatitis B or C: A United States Multicenter Study
260. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin
261. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases
262. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
263. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype
264. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia
265. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B
266. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
267. Development, Optimization and Evaluation of Herbal Patch Formulation for Acne Treatment
268. A Comparison and Validation of Predicted Continuous Positive Airway Pressure Formulas vs Autotitration
269. Classic Hodgkin lymphoma with marked granulomatous reaction: A clinicopathologic study of 20 cases
270. Additional file 1 of A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
271. Genotype 3 Infection: The Last Stand of Hepatitis C Virus
272. Multiplex Protein Analysis to Determine Fibrosis Stage and Progression in Patients With Chronic Hepatitis C
273. Mutation Analysis in Cancer
274. Route Flap Damping Made Usable
275. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
276. Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype
277. Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
278. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
279. A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies
280. ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
281. Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
282. Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years
283. The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
284. Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
285. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort
286. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
287. Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens
288. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
289. The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
290. Lung Cancer Diagnosis by Bronchoscopy at Tertiary Care Center: A Retrospective Analysis
291. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
292. 112. ClinGen Somatic Cancer Variant Interpretation (CVI) committee and the Somatic Cancer expert panel process
293. 128. Clinical testing of mismatch repair in neoplasms using multiple laboratory methods
294. Non‐Alcoholic Fatty Liver Disease
295. RanKer: An AI-Based Employee-Performance Classification Scheme to Rank and Identify Low Performers
296. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF ( FLAG ) in combination with gemtuzumab ozogamicin ( GO ) or Idarubicin ( IDA ) in patients with newly diagnosed core binding factor ( CBF ) acute myelogenous leukemia: MD Anderson experience in 174 patients
297. Differential prognostic impact ofRUNX1mutations according to frontline therapy in patients with acute myeloid leukemia
298. Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods
299. Contemporary outcomes inIDH‐mutated acute myeloid leukemia: The impact of co‐occurringNPM1mutations and venetoclax‐based treatment
300. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD ‐negative remission
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.